A314130 Stock Overview
A clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Genome & Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₩2,620.00 |
| 52 Week High | ₩7,335.00 |
| 52 Week Low | ₩2,470.00 |
| Beta | 1.04 |
| 1 Month Change | -9.03% |
| 3 Month Change | -30.13% |
| 1 Year Change | -58.05% |
| 3 Year Change | -84.90% |
| 5 Year Change | -86.73% |
| Change since IPO | -43.84% |
Recent News & Updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Nov 13
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Recent updates
Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Nov 13Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 31% Share Price Slump
Sep 06Is Genome (KOSDAQ:314130) A Risky Investment?
Jul 03Investors Still Aren't Entirely Convinced By Genome & Company's (KOSDAQ:314130) Revenues Despite 49% Price Jump
May 27Positive Sentiment Still Eludes Genome & Company (KOSDAQ:314130) Following 25% Share Price Slump
Apr 11Is Genome (KOSDAQ:314130) Using Debt In A Risky Way?
Mar 08Genome (KOSDAQ:314130) Is In A Good Position To Deliver On Growth Plans
Mar 17Shareholder Returns
| A314130 | KR Biotechs | KR Market | |
|---|---|---|---|
| 7D | -1.7% | -0.004% | -0.04% |
| 1Y | -58.0% | 8.4% | -12.2% |
Return vs Industry: A314130 underperformed the KR Biotechs industry which returned 9.5% over the past year.
Return vs Market: A314130 underperformed the KR Market which returned -11.6% over the past year.
Price Volatility
| A314130 volatility | |
|---|---|
| A314130 Average Weekly Movement | 11.6% |
| Biotechs Industry Average Movement | 8.8% |
| Market Average Movement | 6.6% |
| 10% most volatile stocks in KR Market | 12.7% |
| 10% least volatile stocks in KR Market | 3.4% |
Stable Share Price: A314130's share price has been volatile over the past 3 months compared to the KR market.
Volatility Over Time: A314130's weekly volatility (12%) has been stable over the past year, but is still higher than 75% of KR stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 100 | Jisoo Pae | genomecom.co.kr |
Genome & Company, a clinical stage biotechnology company, researches and develops novel-targeted immuno-oncology therapeutics in the field of immuno-oncology, skin diseases, and autism in South Korea. Its lead product candidate is GEN-001, an oral microbiome therapeutic candidate developed to have immune modulating activities. The company also develops GEN-501 targeting the non-responders of Dupilumab drugs with atopic skin diseases; and GENA-104 for the treatment of solid tumors, as well as microbiome-based products, including therapeutics, cosmeceuticals, and dietary supplements.
Genome & Company Fundamentals Summary
| A314130 fundamental statistics | |
|---|---|
| Market cap | ₩81.18b |
| Earnings (TTM) | -₩35.67b |
| Revenue (TTM) | ₩24.09b |
3.4x
P/S Ratio-2.3x
P/E RatioIs A314130 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A314130 income statement (TTM) | |
|---|---|
| Revenue | ₩24.09b |
| Cost of Revenue | ₩11.71b |
| Gross Profit | ₩12.38b |
| Other Expenses | ₩48.05b |
| Earnings | -₩35.67b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.15k |
| Gross Margin | 51.40% |
| Net Profit Margin | -148.07% |
| Debt/Equity Ratio | 25.5% |
How did A314130 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/27 06:17 |
| End of Day Share Price | 2024/12/27 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Genome & Company is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|